PARP1 and ovarian carcinoma: Based on the same principle described in the breast cancer section above, three PARP inhibitors (olaparib [286], rucaparib [287], and niraparib [250]) were approved as maintenance therapies for BRCA1/2-mutated ovarian cancer [288–290] (Fig. 4c).